Conflicts and humanitarian crises create new HIV vulnerabilities
US funding cuts cause immediate drops in numbers testing and on HIV treatment
Broadly neutralising antibodies plus immune modulator may delay HIV rebound
Lenacapavir and cabotegravir PrEP supported for use in pregnancy and breastfeeding
Injectable HIV treatment works for people with poor HIV control in Africa
Intermittent HIV treatment dosing may be a response to the funding crisis, but adolescent study raises concerns
Scaling back PEPFAR will leave 700,000 without PrEP and cause 6700 new HIV infections within a year
Treatment changes do not reduce weight in people with HIV
Once-monthly oral PrEP moves into late-stage trials
